/
GHRS
$28.49+$0.27 (+0.96%)live
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.9B
69M shares
52-week range
$11.32 – $28.96
97% from low
Exchange
NASDAQ
CS
Borrow rate
0.59%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$6.76
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 | $0 | $0 | $335.0K |
| Gross profit | $0 | $0 | $0 | $0 | $0 | $0 | −$335.0K |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $296.0K | $338.0K | $8.6M | $20.5M | $29.8M | $35.0M | $38.7M |
| Operating income | −$310.0K | −$446.0K | −$15.1M | −$30.6M | −$41.2M | −$50.3M | −$60.7M |
| EBITDA | $0 | $0 | −$9.2M | −$22.4M | −$35.2M | −$38.6M | −$47.5M |
| Net income | −$310.0K | −$446.0K | −$9.2M | −$22.5M | −$35.6M | −$39.0M | −$48.3M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.01 | -0.01 | -0.18 | -0.14 | -0.68 | -0.75 | -0.79 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-1.40 | $-1.48–$-1.16 | 7 |
| 2027 | $51M | $-2.00 | $-2.42–$-1.42 | 6 |
| 2028 | $766667 | $-2.24 | $-3.66–$-1.56 | 7 |
| 2029 | $45M | $-2.12 | $-2.12–$-2.12 | 2 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$3.99
Price
$28.49
Implied downside
-86%
Peer comparison
GH Research PLC Ordinary Shares
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
www.ghres.com- Employees
- 73
- IPO / List date
- Jun 25, 2021
Held by traders on TradeandTell
No one on the platform currently holds GHRS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in GHRS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded GHRS yet.
